Frontier Pharma Alzheimer’s Disease and Associated Indications Frontier Pharma Alzheimer’s Disease and Associated | Page 3

- Which first-in-class pipeline products have no prior involvement in licensing or co-development
deals?
Reasons to buy
This report will allow you to -
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis,
etiology, epidemiology, symptoms, diagnosis and treatment options.
- Identify leading products and key unmet needs within the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule
type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments,
first-in-class targets in the pipeline have been assessed and ranked according to clinical potential.
Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety,
depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in
greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-
development deals that may represent potential investment opportunities.
Download sample Copy of This Report at:
http://www.radiantinsights.com/research/frontier-pharma--alzheimers-disease-and-
associated-indications/request-sample
Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Executive Summary 6
2.1 Limited Treatment Options despite Large Market Opportunity 6
2.2 Exceptionally High Level of First-in-Class Innovation within Alzheimer’s Disease Pipeline 6
2.3 Active Deals Landscape Dominated by GPCR-Targeting Products 6
Follow Us: